Showing results (2821-2830 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|June 7, 1995
Assessing the economic value of a new antidepressant. A willingness-to-pay approachB J O'Brien, S Novosel, G Torrance, et al.Pharmacoeconomics|February 8, 1992
Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapyB S BloomPharmacoeconomics|September 5, 1995
Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysisB S Bloom, A L Hillman, B LaMont, et al.Pharmacoeconomics|February 8, 2006
Sociodemographic differences in quality of life in rheumatoid arthritisErik J Groessl, Theodore G Ganiats, Andrew J SarkinPharmacoeconomics|February 1, 2006
Interstitial Cystitis: Cost, treatment and co-morbidities in an employed populationEric Q Wu, Howard Birnbaum, Milena Mareva, et al.Pharmacoeconomics|February 1, 2006
Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosisAntonio Gómez-Outes, Eduardo Rocha, Javier Martínez-González, et al.Pharmacoeconomics|February 1, 2006
Economic evaluation of rivastigmine in patients with Parkinson's disease dementiaAndrew R Willan, Ron Goeree, Eleanor M Pullenayegum, et al.Pharmacoeconomics|September 18, 2009
Head lice treatments and school policies in the US in an era of emerging resistance: a cost-effectiveness analysisItzhak Gur, Ronald SchneeweissPharmacoeconomics|September 18, 2009
Utilities of the EQ-5D: transferable or not?Saskia Knies, Silvia M A A Evers, Math J J M Candel, et al.Pharmacoeconomics|June 28, 2006
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UKSophie Beale, Adrian Bagust, Arran T Shearer, et al.Pageof 336